Windlas Biotech FY26 Revenue at ₹904 Crore, Up 19% YoY
Windlas Biotech reported FY26 revenue of ₹904 crore, up 19% YoY, and Q4FY26 revenue of ₹238 crore, up 18% YoY. Adjusted EBITDA for FY26 was ₹121 crore, a 26% increase. Adjusted PAT grew 31% to ₹83 crore. The company proposed a dividend of ₹6.30 per share for FY26. Plant-6 is on track for commercialization by H1 FY27.
The announcement showcases significant revenue and profit growth, along with strategic expansions and dividend announcements, likely to positively influence investor confidence and market perception.
The announcement highlights strong financial performance, including record revenues and profit growth, along with positive future prospects and expansion plans.
Windlas Biotech Limited reported its Q4 and FY26 financial results. The company achieved its 13th consecutive quarter of record revenue, with ₹238 crore in Q4FY26. The highest-ever revenue reached ₹904 crore for FY26, marking a 19% year-over-year growth. CDMO revenue also hit a record high of ₹664 crore, a 20% increase year-over-year. Adjusted EBITDA stood at ₹121 crore, up 26% YoY, and adjusted PAT grew by 31% YoY to ₹83 crore. EPS grew 8% YoY, from ₹29.19 to ₹31.60 in FY26. The company reported a strong net liquidity of ₹251 crore and is net debt-free. Cash generated from operations was ₹105 crore.
Mr. Hitesh Windlass, Managing Director, commented that despite moderate industry volume growth, the company delivered a strong performance with a focus on scalability, durability, and profitability. Ms. Komal Gupta, CEO & CFO, mentioned that FY26 was a defining year, with revenues crossing ₹900 crore for the first time, closing at ₹904 crore, a 19% YoY growth. The company has proposed a dividend of ₹13 crore (₹6.30 per share) for FY26.
Plant-4 and Plant-5 (Injectable Facility) received GMP certification from the Philippines. Plant-6 has achieved mechanical completion and is on track for commercialization by H1 FY27.
What to do with a filing like this
Windlas Biotech Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Windlas Biotech Limited. Read the original for the full detail.